GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Price-to-Owner-Earnings

CLRPF (Clarity Pharmaceuticals) Price-to-Owner-Earnings : (As of Dec. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-12-15), Clarity Pharmaceuticals's share price is $2.8581. Clarity Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Clarity Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


CLRPF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.405
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-15), Clarity Pharmaceuticals's share price is $2.8581. Clarity Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.10. Therefore, Clarity Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-15), Clarity Pharmaceuticals's share price is $2.8581. Clarity Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.10. Therefore, Clarity Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Clarity Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Clarity Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Price-to-Owner-Earnings Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24
Price-to-Owner-Earnings
- - -

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial - - - - -

Competitive Comparison of Clarity Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Clarity Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Price-to-Owner-Earnings falls into.



Clarity Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Clarity Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.8581/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals  (OTCPK:CLRPF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Clarity Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.